

FUTURE PLANS AND USE OF [REDACTED]

FUTURE PLANS

Please see “Business — Our Strategies” for a detailed discussion of our future plans.

USE OF [REDACTED]

We estimate that we will receive aggregate [REDACTED] of approximately HK\$[REDACTED] from the [REDACTED] after deducting the [REDACTED] and estimated expenses in connection with the [REDACTED] paid and payable by us, assuming no [REDACTED] is exercised and an [REDACTED] of HK\$[REDACTED] per H Share, being the mid-point of the indicative [REDACTED] of HK\$[REDACTED] to HK\$[REDACTED] per H Share in this document.

We currently intend to use the [REDACTED] from the [REDACTED] for the following purposes, subject to changes in light of our evolving business needs and changing market conditions:

	Year ended December 31,						Approximate % of the total
	2026	2027	2028	2029	2030	Total	[REDACTED]
	(HK\$ million)						
Research and development of our pipeline products for our clinical sequencing solutions	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]%
Expand our scientific research sequencing solutions and update relevant technologies	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]%
Upgrade and transform our existing laboratories and manufacturing facilities	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]%
Business development in our clinical sequencing solutions and scientific research sequencing solutions domestically and overseas	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]%
Working capital and general corporate purposes	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]%
Total	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	100.0%

- approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED] million, will be invested in the research and development of our pipeline products for our clinical sequencing solutions over the next five years. In particular,
 - o approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to the research and development of our pipeline IVD products, out of which (i) approximately HK\$[REDACTED] will be used for U+ test kits, (ii) approximately HK\$[REDACTED] will be used for expanded carrier screening test kits (擴

FUTURE PLANS AND USE OF [REDACTED]

展型攜帶者篩查試劑盒), (iii) approximately HK\$[REDACTED] will be used for genetic hearing loss test kits (遺傳性耳聾檢測試劑盒), (iv) approximately HK\$[REDACTED] will be used for the commercialization P-tau-181 test kits and A β 1–42 test kits for Alzheimer’s disease early diagnosis, and (v) approximately HK\$[REDACTED] will be used for thalassemia test kits (地中海貧血檢測試劑盒). Specifically, we plan to (i) continue our ongoing and planned clinical trials; (ii) conduct performance studies and registration testing for our pipeline IVD products; and (iii) complete regulatory compliance procedures for our pipeline IVD products. The aforementioned research and development activities are scheduled to take place between 2026 and 2030. For details about our latest development stage and expected timetable of the aforementioned pipeline products, see “Business — Overview — Our IVD Product Development Pipeline.”

- o approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to upgrade our equipment and instruments as well as R&D and registration of our new products, out of which (i) approximately HK\$[REDACTED] will be used for upgrading our NextSeq 550AR, (ii) approximately HK\$[REDACTED] will be used for commercialization for Dx200 analyzer and Dx200S analyzers (全自動螢光免疫分析儀Dx200分析儀和Dx200S分析儀), and (iii) approximately HK\$[REDACTED] will be used for purchases of single-molecule sequencer (單分子測序儀) for the research and development of thalassemia test kits, as well as their respective supporting software.
- approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be invested in upgrading and transforming our existing laboratories and manufacturing facilities over the next five years. In particular,
 - o approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to upgrade manufacturing and laboratory facilities by transforming our existing laboratories and with technologically advanced sample storage equipment, biosafety equipment and environmental control equipment. In particular, we plan to (i) carry out renovation and construction for our scientific research sequencing laboratory and our IVD production plant. Specifically, we intend to repair and replace aged facilities and sequencing equipment within the laboratory in Beijing over the next five years. This includes a comprehensive renovation of the laboratory space, featuring critical upgrades to the ventilation, air conditioning and pressure control systems to ensure a controlled environment suitable for scientific sequencing. Furthermore, we will acquire new equipment to facilitate our scientific research sequencing solutions, including nucleic acid transfer systems, PCR instruments, real-time PCR systems, capillary electrophoresis detection systems, refrigerated and high-speed centrifuges, cryostat, single-cell microfluidic generation systems, cell counters, as well as various single-channel, multi-channel, and electric pipettes. In addition, in alignment with the expected growth of our scientific

FUTURE PLANS AND USE OF [REDACTED]

research sequencing solutions business, we plan to construct with new, advanced facilities and equipment in our laboratory in Beijing and other regions where we have established market presence, such as regions nearby Beijing and Southern China, over the next five years to significantly increase our service throughput and technological capabilities. We plan to acquire new advanced genetic sequencers capable of various sequencing types, thereby enabling new scientific research sequencing types with high gross margins. In particular, we plan to deploy advanced sequencers to perform single-cell sequencing efficiently and to enable advanced sequencing types such as multi-level tandem third-generation full-length transcriptome and spatial third-generation full-length transcriptome sequencing, which enjoy high gross margins. To support our IVD manufacturing operations, we plan to procure specialized cold chain and ambient temperature storage facilities to ensure optimal preservation conditions for both raw materials and finished IVD products. Concurrently, we intend to establish and equip new IVD production workshops and quality inspection laboratories. We also plan to implement advanced digital infrastructure, including a document management system (DMS), a unique device identification (UDI) system, and comprehensive production and GMP quality management systems. We believe these capital investments are well-founded, as we anticipate a significant increase in production capacity utilization driven by the continued commercialization of our CNV-seq kits and the scheduled launch of additional IVD products in the near term; (ii) upgrade our sample storage equipment. In anticipation of the growing sample volume, we advanced ultra-low temperature freezers and liquid nitrogen storage systems, all integrated with an intelligent information management system. This upgrade will enable the high-throughput, orderly, and efficient storage and retrieval of millions of biological samples, thereby optimizing our space utilization, enhancing our sample processing capacity and supporting the continued expansion of our scientific research sequencing solutions; (iii) enhance our biosafety equipment such as high-efficiency air filtration systems and biosafety cabinets to ensure the operational safety during the sequencing process and the integrity of biological samples; and (iv) improve our environmental control through laboratory space renovation and rezoning, as well as upgrading our negative and positive pressure environmental control systems to meet cleanliness requirements for various experimental processes.

FUTURE PLANS AND USE OF [REDACTED]

The following table sets forth the breakdown of the [REDACTED] allocated to upgrade manufacturing and laboratory facilities.

	2026	2027	2028	2029	2030
	<i>(HKD in millions)</i>				
Renovation and construction of laboratories	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Upgrade sample storage equipment	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Enhance biosafety equipment	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Improve environmental control	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

- o approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to upgrade our laboratories by automating our sequencing and wet lab process and introducing intelligent laboratory management system. We plan to (i) set up our robotic arms and sensors for core processes such as nucleic acid extraction, library construction and pooling; and (ii) deploy intelligent laboratory management system by adopting our proprietary software to monitor equipment and task status for tested samples. Currently, critical workflows such as sample management, personalized library construction and library pooling are entirely manual, while other processes still require constant manual supervision. As we process a surging volume of samples and sequencing data, our current operational capacity face significant bottlenecks. The automated sequencing and wet lab processes and intelligent laboratory management system are therefore crucial to enhance our operational efficiency, increase throughput, ensure quality and consistency, and reduce costs.

The following table sets forth the breakdown of the [REDACTED] allocated to automating our laboratories.

	2026	2027	2028	2029	2030
	<i>(HKD in millions)</i>				
Automated production line	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
Intelligent laboratory management system	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

FUTURE PLANS AND USE OF [REDACTED]

- approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED] million, will be invested for business development in our clinical sequencing solutions and scientific research sequencing solutions in the domestic market as well as our overseas business development over the next five years. In particular,
 - o approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to expand our sales and marketing team for our clinical sequencing solutions in the domestic market to facilitate the expansion of our business and carry out relevant marketing and promotional activities such as attending academic conferences, providing training dealers and customers, conducting lectures and cooperating with industry KOLs for this line of business. For example, we plan to recruit over 20 sales and marketing personnel to meet the need of market penetration for our new products. Specifically, we plan to recruit four, two, four, seven and six sales and marketing personnel in 2026, 2027, 2028, 2029 and 2030, respectively, primarily responsible for promoting the sales of our CNV-seq kits and upcoming AD kits. Our newly recruited sales and marketing personnel will be located in China, focusing on geographical markets where we have already established presence.
 - o approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to expand our sales and marketing team for our scientific research solutions in the domestic market. For example, we plan to recruit two, two, two, two and two sales and marketing personnel for our scientific research sequencing solution in 2026, 2027, 2028, 2029 and 2030, respectively, responsible for promoting new types of scientific research sequencing and facilitating customer support. We recruit personnel primarily from provinces with prominent research and academic institutions.
 - o approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated for the development and promotion of our products and services in overseas markets. We plan to enter into collaborations with domestic hospitals, research institutions and healthcare institutions in Southeast Asia and the Middle East. We consider the expansion of our business into Southeast Asia and the Middle East to be feasible, given the less mature competitive landscape in these regions compared to the China’s market. These regions have preliminary competitive landscape of genetic sequencing, which primarily comprises Chinese companies as existing players. Our expansion plan prioritizes the scientific research sequencing solutions business, focusing initially on nurturing customer relationships and achieving preliminary sales before extending to our clinical sequencing solutions. We possess several competitive advantages, including our focused technical expertise in specialized areas such as resequencing, transcriptome regulation sequencing, and single-cell and spatial sequencing solutions. We had certain customers through referrals from existing scientific research sequencing solutions customers, enabling preliminary sales and demonstrating recognition of our service quality. Specifically, we plan to partner with hospitals and

FUTURE PLANS AND USE OF [REDACTED]

- institutions in (i) constructing local testing and technology transfer production lines, (ii) developing local testing scenarios, (iii) strengthening local healthcare ecosystems, and (iv) establishing overseas laboratories for scientific research innovation and technology transfer.
- approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED] million, will be invested in expanding our scientific research sequencing solutions and updating relevant technologies over the next five years. In particular,
 - approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to further diversify our scientific research sequencing solutions by developing spatial transcriptomics (時空轉錄組學), high-sensitivity proteomics platform (高靈敏蛋白質組學平台) and nanopore single-molecule sequencing platform (納米孔單分子測序平台). To strengthen these initiatives, we plan to enhance the performance of our scientific research sequencing solutions through (i) improved sequencing accuracy and efficiency via introducing automated sample loading modules, (ii) upgraded analysis software incorporating advanced algorithms to enable multi-task parallel sequencing and increase daily single-device sample throughput, (iii) systematic upgrading of core testing equipment, and (iv) implementing intelligent technology-driven service production lines. We also plan to expand platform compatibility with diverse sample types and broaden application scenarios across biomedical research and clinical diagnostics.
 - approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to recruit additional qualified scientific research and technical personnel for our scientific research sequencing solutions. We plan to recruit technical and research talents with extensive industry experience in the fields of molecular biology, cell biology and bioinformatics.
 - approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be allocated to upgrade our high-performance analytical platform so as to enhance our bioinformatics analysis capabilities and efficiency.
 - approximately [REDACTED]% of the net [REDACTED] from the [REDACTED], or HK\$[REDACTED], will be used for working capital and general corporate purposes.

If we make an upward or downward [REDACTED] adjustment to set the final [REDACTED] to be above or below the mid-point of the [REDACTED], we will increase or decrease the allocation of the net [REDACTED] to the above purposes on a pro rata basis.

The additional net [REDACTED] that we would receive if the [REDACTED] were exercised in full would be (i) HK\$[REDACTED] (assuming an [REDACTED] of HK\$[REDACTED] per H Share, being the high end of the indicative [REDACTED]), (ii) HK\$[REDACTED] (assuming an [REDACTED] of HK\$[REDACTED] per H Share, being the mid-point of the indicative [REDACTED]) and (iii) HK\$[REDACTED] (assuming an [REDACTED] of HK\$[REDACTED] per H Share, being the low end of the indicative [REDACTED]).

THIS DOCUMENT IS IN DRAFT FORM. THE INFORMATION CONTAINED HEREIN IS INCOMPLETE AND IS SUBJECT TO CHANGE. THIS DOCUMENT MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT.

FUTURE PLANS AND USE OF [REDACTED]

We will only place the net [REDACTED] of the [REDACTED] that are not immediately used for the above purposes in short-term interest-bearing accounts at licensed commercial banks and/or authorized financial institutions as defined under the Securities and Futures Ordinance or applicable laws and regulations in other jurisdictions so long as it is deemed to be in the best interests of our Company. In such event, we will comply with the appropriate disclosure requirements under the Listing Rules.